MedTrace Logo

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

NCT05376722 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-01-05

No results posted yet for this study

Summary

To evaluate the pathological response rate of pamiparib combined with abiraterone acetate in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer after radical prostatectomy

Conditions

  • Neoadjuvant Therapy

Interventions

DRUG

pamiparib

pamiparib 40 mg orally, twice a day

DRUG

abiraterone

biraterone acetate 1000 mg orally, once a day

DRUG

prednisone

prednisone acetate tablets (prednisone) 5 mg, once a day

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • The First Affiliated Hospital of Soochow University

    collaborator OTHER

  • Nanjing First Hospital, Nanjing Medical University

    collaborator OTHER

  • Hongqian Guo

    lead OTHER

Principal Investigators

  • shun zhang, Dr. · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2023-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05376722 on ClinicalTrials.gov